BMRN

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Retrieved on: 
Thursday, March 7, 2024
Cristin, SAN, School, Ophthalmology, Roche, Growth, Public health, MBA, Molecular biology, Postgraduate education, University, Haemophilia, Business, BioMarin Pharmaceutical, Triple accreditation, Patient, Infection, BMRN

SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

Key Points: 
  • SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
  • Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
  • Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries.
  • He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.

BioMarin Scheduled to Participate in March Investor Conferences

Retrieved on: 
Friday, March 1, 2024
SAN, BioMarin Pharmaceutical, Conference, BMRN, Pharmaceutical industry

SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.

Key Points: 
  • SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.
  • Cowen 44th Annual Healthcare Conference (Boston, MA)
    Leerink Partners Global BioPharma Conference (Miami, FL)
    Jefferies Biotech on the Bay Summit (Miami, FL)
    Barclays 26th Annual Global Healthcare Conference (Miami, FL)
    The live webcast of the fireside chat can be accessed by visiting BioMarin's website at https://investors.biomarin.com/ .
  • A webcast replay will be available through the Company's website for a limited time following the conferences.

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

Retrieved on: 
Thursday, February 8, 2024
BioMarin Pharmaceutical, SAN, BMRN, Webcast, Interest

SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.
  • ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 800-770-2030
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

Retrieved on: 
Wednesday, January 3, 2024
BMRN, Conference, BioMarin Pharmaceutical, SAN

SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California.

Key Points: 
  • SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California.
  • An audio webcast of the presentations will be available live.
  • You can access the webcasts at: https://investors.biomarin.com/ .
  • An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023
Adverum Biotechnologies, University, Ambit Biosciences, Daiichi Sankyo, Hill-Rom, Indiana University, Harvard Law School, Baxter, Acceleration, Strategy, Palmer, Pfizer, Biotechnology Innovation Organization, Invacare, Eli Lilly, Hospira, Pediatrics, Chairperson, The Nature Conservancy, Genzyme, American Cancer Society, Therapy, Goldman Sachs, M.B.A, BMRN, ImmunoGen, DSM-IV codes, Shire (pharmaceutical company), IPO, Patient, Proteostasis, BioMarin Pharmaceutical, Corporate development, Dentsply Sirona, Senior, Syneos Health, Iovance Biotherapeutics, Sclerosis, Acquisition, SAN, CIO, Eli Lilly and Company, Interim, Bristol Myers Squibb, Information technology, Management

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.

BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET

Retrieved on: 
Tuesday, October 17, 2023
BioMarin Pharmaceutical, Interest, Webcast, SAN, U.S.–Canada Team Tournament (Go), BMRN

SAN RAFAEL, Calif., Oct. 17, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., Oct. 17, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m.
  • ET to discuss third-quarter 2023 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 800-770-2030
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Wednesday, September 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

BioMarin to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 5, 2023
BMRN, SAN, Cryptocurrency, Broadcasting

SAN RAFAEL, Calif., Sept. 5, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September.

Key Points: 
  • SAN RAFAEL, Calif., Sept. 5, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September.
  • An audio webcast of the presentations will be available live.
  • You can access the webcasts at: https://investors.biomarin.com/ .
  • An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

Retrieved on: 
Wednesday, August 9, 2023
Precigen, Maxar Technologies, Levi, Synchrony Financial, BMRN, SYF, NYSE, Pharmaceutical industry, Insurance

NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against each of these companies.

Key Points: 
  • NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against each of these companies.
  • Maxar Technologies, Inc. (NYSE: MAXR) - A settlement was reached in the class action against Maxar Technologies Inc. in which a settlement fund of $27,000,000 was created for the benefit of class members.
  • Precigen, Inc. (Nasdaq: PGEN) - A settlement was reached in the class action against Precigen, Inc. in which a settlement fund of $13,000,000 was created for the benefit of class members.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET

Retrieved on: 
Wednesday, July 12, 2023
U.S.–Canada Team Tournament (Go), Interest, Webcast, BMRN, SAN, BioMarin Pharmaceutical, Cryptocurrency

SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m.
  • ET to discuss second-quarter 2023 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 877-674-7070
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.